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DO CALCIUM CHANNEL BLOCKERS PROTECT AGAINST FIRST DOSE 
REACTION TO OKT3? Eric A. Richard, and Margaret J. Bia. Section of 
Nephrology, Department of Internal Medicine, Yale University School 
of Medicine, New Haven, CT. 
Abstract 
OKT3 is a monoclonal antibody used as an immunosuppressant 
to treat rejection or to prevent cyclosporine toxicity in the setting 
of post-operative delayed graft functioning. Use of OKT3 is often 
complicated by a first dose reaction, ranging from a mild reaction to 
a life threatening complication. OKT3 binding to human T 
lymphocytes promotes an influx of calcium, which stimulates 
mitogenesis and a release of lymphokines (the proposed cause of 
this clinical syndrome). Since calcium channel blockers can inhibit 
T lymphocyte activation in vitro, this study was performed to 
determine if clinically used doses of calcium channel blockers 
decrease the severity of first dose reaction to OKT3. 
A retrospective, chart review study was employed to analyze 
the incidence of side effects of patients on calcium channel blockers 
(N=20) as compared to those who were not (N=49). The calcium 
channel blocker group consisted of 13 patients on nifedipine (30- 
120 mg/day), 5 on verapamil (120-480 mg/day), and 2 on diltiazem 
(90-180 mg/day). All patients received OKT3 (5mg) after being 
premedicated with acetaminophen, diphenhydramine, and varying 
amounts of glucocorticoids. The two groups were similar in age, 
sex, race, percent on dialysis, and percent who had received 

cadaveric transplants. Dose of azathioprine, dose of methyl- 
prednisolone, and both the dose and level of cyclosporine were also 
similar in the two groups. 
There were no differences between the two groups in the 
frequency of the fever or the magnitude of the fever spike. The two 
groups were also similar in the frequencies of chills, Gl upset, 
hemodynamic changes, and respiratory symptoms. Only the symptom 
of fatigue was different, occurring more often in the calcium 
channel blocker group. The data suggest that clinically used doses 
of calcium channel blockers do not protect against first dose 
reaction to OKT3 perhaps because these doses do not achieve plasma 
levels high enough to inhibit T cell activation and subsequent 
lymphokine release. 
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Introduction 
The monoclonal antibody OKT3 is a powerful 
immunosuppressant used in renal transplant patients as therapy to 
treat resistant rejection and to avoid cyclosporine nephrotoxicity in 
the clinical setting of post-operative delayed graft functioning. 
First and second doses of OKT3 are associated with a well described 
clinical syndrome that is known as "first dose reaction to OKT3". 
The syndrome consists of fever, chills, hemodynamic changes, Gl 
upset, and neurological changes. Initial premedication with 
acetaminophen, diphenhydramine and glucocorticoids has not been 
able to eliminate this syndrome. Although infrequently life 
threatening, this adverse drug reaction is an important source of 
patient discomfort. This adverse reaction may result from an OKT3 
induced T cell activation, leading to the production and release of 
lymphokines. This activation appears to use calcium as a second 
messenger, and, in vitro, calcium channel blockers decrease the 
production of lymphokines. This study examines whether clinically 
used doses of calcium channel blockers can decrease the first dose 
reaction to OKT3. 
General Description 
Human T cells detect antigen, leading to subsequent activation 
and proliferation, via a T cell receptor(TCR)/CD3 complex (1). Proof 
(2) that a TCR/CD3 complex exists includes that CD3 
immunoprecipitates with TCR, CD3 comodulates with TCR, and a 
stoichiometric relationship exists between CD3 and TCR. Consisting 
of a and (3 subunits, the TCR recognizes the specific antigen; the CD3 
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subunit, which is non-covalently linked to the TCR 3 subunit, 
transduces the antigen-binding signal into the T cell. 
Phosphorylation of the CD3 complex post TCR occupancy (3) lends 
proof that CD3 is the signal transducer. Furthermore, human 
monoclonal antibodies which bind to the CD3 complex induce an 
increase in intracellular calcium (2,4), T cell proliferation (2), and 
lymphokine production (5,6,7,8) - all similar events to what occurs 
after antigen binds to the TCR. Present on all mature T cells and 
late thymocytes (1), the CD3 complex consists of 3 invariant 
subunits - 2 glycoproteins (y and 5) and 1 non-glycosylated 
hydrophobic polypeptide (e). Because its intracellular component is 
larger than its extracellular, CD38 is postulated to be the actual 
signal transducer in man. 
Initially developed in 1978 to differentiate between T cell 
subsets (9), the monoclonal antibody OKT3 binds to a 20kd subunit of 
the CD3 complex. In fact, the term CD3 was subsequently derived 
from OKT3. The first monoclonal antibody used in humans, OKT3 is 
an lgG2a immunoglobulin and consists of a 50kd heavy chain and a 
25kd light chain. Derived from a hybridoma and grown as an ascites 
in pathogen free, standard bred mice, OKT3 is purified to be free of 
both pyrogens and pathogens. 
Immunosuppression 
OKT3 exerts its powerful immunosuppressive actions 
(10,11,12,13) by removing CD3+ cells from the circulation (usually 
within 1 hour) and by blocking the killer function of sessile T cells 
(the would be kiiler cells in the allograft) - as described below. 
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After the 0KT3 antibody binds to the CD3 complex, this complex is 
opsonized and is either removed by the reticulo-endothelial system 
via lysis or redistributed to lymph nodes. Furthermore, similar to 
high levels of antigen, OKT3 effectively modulates, or removes, not 
only the CD3 antigen from the T cell surface but also the TCR, 
making these T cells non-functional. 
Studies by Gebel(14) have shown that in renal transplant 
patients, circulating CD3 cells are diminished from 70% to <1% after 
one dose of OKT3. Within 2 days, CD3 cells returned to the 
circulation with greatly decreased density of the CD3 molecule and 
no co-expression of TCR. Failing to proliferate post allogenic 
stimulation in vitro, these CD3- cells were nonfunctional and 
immuno-incompetent. Because CD3+ cells returned to the 
circulation and lymph nodes once OKT3 was stopped, this process 
was reversible. Similarly, Zlabiger(15) and Caillot-Zucman(16), by 
showing modulation of CD3 cells, added further evidence for this 
phenomenon. As T cell depletion was only 20-60% in the lymph 
nodes, modulation plays a more vital role. More importantly(17), in 
the allograft, some CD3+ cells were present but nonfunctional and 
without the TCR. Therefore, because of the effects of modulation, 
the modulated T cells were incapable of mounting an immune 
response against the allograft. Reappearance of the CD3 complex 
may have indicated failure of therapy, perhaps secondary to the 
development of anti-OKT3 antibodies. 
The inhibition of T cell killing capacity is another powerful 
immunosuppressive mechanism of OKT3. Landegren(18), using cell 
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cultures of peripheral blood lymphocytes from healthy volunteers, 
showed that OKT3 blocked cytotoxic T cell lysis by impeding the 
ability of the cytotoxic T lymphocytes to lyse bound cells, rather 
than by reducing target binding. However, Seventer(19), using a 
panel of anti-CD3 monoclonal antibodies which included OKT3, 
demonstrated that OKT3 inhibited target cell recognition by the 
cytotoxic T lymphocytes via steric hindrance or confirmational 
changes. Nonetheless, the cytotoxic T lymphocytes blocking 
capacity occurred in vitro at normal therapeutic trough levels of 
lug/ml (for 5mg dose). 
Clinical Trials 
Many clinical trials have suggested that OKT3 is successful 
when used as treatment against rejection (both primary and 
resistant) and as prophylaxis in the early post transplant period. 
Treating 8 cadaver renal allograft recipients undergoing acute 
rejection, Cosimi(20) reported on the first clinical trial using OKT3. 
This monoclonal antibody offered several advantages over polyclonal 
antibodies - mainly homogeneity, ease of use and monitoring, and 
lower toxicity. Within 2-7 days, OKT3 reversed rejection in all 8 
case with a 75% 12 month graft survival. Similarly, in a large, 
prospective, randomized, multicenter study(21), 123 patients were 
treated with 14 days of OKT3 vs conventional high dose steroids. 
The results showed reversal in 94% vs 75% and 1 year survival at 
62% vs 45% (OKT3 vs steroids). The efficacy of OKT3 in these initial 
trials set the stage for use in other transplant settings. 
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Many studies have suggested that 0KT3 is efficacious in the 
primary treatment of rejection (22,23) and in the treatment of both 
steroid resistant (23,24,26-30) and ATG/steroid resistant rejection 
(22,24,30). Some investigators(28) suggested treating rejection 
with a pulse of high dose steroid; if successful, this obviates the 
need for OKT3 therapy. Some have also shown some success with 
OKT3 as a prophylactic agent against rejection (25,34-40) and in the 
setting of post-operative delayed graft functioning (25,31), where 
clinicians are hesitant to use cyclosporine with its associated 
nephrotoxicity. Researchers (32,33) have used OKT3 concomitantly 
with cyclosporine with good success in the treatment of rejection; 
in fact, cyclosporine may have reduced the formation of anti-OKT3 
antibodies and increased the efficacy of OKT3 (32). 
If it has been used as a prophylactic agent against rejection in 
the early post-op period, OKT3 can be re-used to treat rejection 
episodes (41,42). Because OKT3 is a murine derived product, 
antibodies to OKT3 can form after initial administration of OKT3. 
Presence of low titre anti-OKT3 antibodies does not preclude re¬ 
treatment with OKT3. However, the number of doses of OKT3 needed 
to deplete CD3 cells from the circulation can be greater in the 
retreated patients as compared with first time receivers of OKT3 
(41). Furthermore, it may be necessary to increase the dose of OKT3 
in retreatment groups to achieve adequate serum OKT3 levels and to 
deplete CD3 cells. Presence of high titre antibodies is a contra¬ 
indication to re-use of OKT3(41) as OKT3 is rarely effective in this 
situation. 
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Side Effects of OKT3 
In the first clinical trial (20), which used a small patient 
sample of 8 patients, chills, a febrile response and an occasional 
wheeze on the first day were noted. This adverse drug reaction 
appeared quite mild and was easily treated with antihistamines and 
acetaminophen. In the multicenter study (21) in 1985, adverse drug 
reactions were first recognized as being important. These reactions 
began 45-60 minutes after the first injection (sometimes second, 
and never subsequent) and lasted several hours. Reported signs and 
symptoms included fever (73%), chills (57%), tremor (10%), dyspnea 
(21%), chest pain/tightness (14%), wheeze (11%), nausea (11%), and 
vomiting (13%). One patient in a state of fluid overload developed 
pulmonary edema. Because of the timing of these signs and 
symptoms after the first or second dose (and rarely subsequent), the 
syndrome has been labeled "first dose reaction to OKT3”. 
Subsequent studies (20,22,25,27,34,38,43,44) have shown 
similar side effects, in addition to others, occurring at significant 
rates. The signs and symptoms that have occurred frequently enough 
so that multiple investigators have reported them include fever, 
chills, hemodynamic sequelae (tachycardia, changes in blood 
pressure), gastro-intestinal upset (vomiting, diarrhea), CNS changes 
(headache, seizure, malaise, aseptic meningitis), respiratory 
distress (dyspnea, wheeze, chest pain/tightness) and 
arthralgias/myalgias. The symptoms of acute rejection can mimic 
OKT3-related symptomatology. Similarly, OKT3 reactions are 
difficult to distinguish from normal post-op recovery. 
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Fever and chills, respiratory and hemodynamic sequelae are the 
most frequent first dose side effects which occur in the first few 
hours (43). Hypertension and mild dyspnea are associated with a 
state of relative fluid overload. This is why many protocols include 
a diuresis/dialysis to <103% of ideal body weight prior to OKT3. 
Furthermore, hypotension and tachycardia have been associated with 
a state of relative volume depletion, often secondary to over 
aggressive diuresis and dialysis. 
Gastro-intestinal and CNS side effects usually appear between 
days 2-3 of OKT3 therapy. These symptoms are usually transient 
and self-limiting and stop after OKT3 is withdrawn.. Aseptic 
meningitis with symptoms of headache, fever, photophobia, nuchal 
rigidity, and mental status changes (43) has occurred in a small 
percentage of patients. Lumbar puncture shows leukocytosis, 
elevated protein, normal glucose, and negative cultures. One 
possible cause (45) for aseptic meningitis is that OKT3 cross reacts 
with a neural antigen, promoting local inflammation. Seizures can 
also occur, with one study (43) showing an association with post-op 
delayed graft functioning. 
Mechanism of Reaction to OKT3 
From the initial studies, it was suggested that the first dose 
reaction was caused by a release of endogenous pyrogens from lysed 
T cells (21). These first dose symptoms were not attributed to 
hypersensitivity for the following reasons - 1) they occurred in 
almost all patients without previous exposure to murine 
immunoglobulin, 2) skin tests prior to OKT3 were routinely negative, 
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and 3) symptoms did not recur with later injections. Because many 
of the side effects were similar to those after systemic 
administration of interleukin-2 (IL-2) and after endotoxic shock 
mediated by tumor necrosis factor-a (TNF-a), lymphokines began to 
be investigated as the cause of the OKT3 induced clinical syndrome. 
Lymphokines are well characterized as mediators of both 
inflammatory and immune reactions (12,46,47,48). Interleukin-2 
(IL-2), produced in T cells and known also as T-cell growth factor, 
has been clearly implicated in inducing T cell proliferation and 
differentiation. Rosenberg (46) described an adverse clinical 
reaction in cancer patients who received high dose IL-2 with 
lymphokine activated cells. Symptoms reminiscent of OKT3 included 
fever, vomiting, diarrhea, fatigue, and chills. Furthermore, he 
described a scenario of increased capillary permeability (leading to 
pulmonary edema) and decreased vascular resistance (leading to 
hypotension). In fact, 34 out of 180 treatment courses were 
complicated by pulmonary edema; 16 patients required intubation 
(46). 
Tumor necrosis factor-a (TNF-a), or cachectin, has been 
implicated as a mediator of cachexia in cancer patients and 
endotoxic shock in patients with gram negative sepsis. Produced by 
both monocytes and T cells, TNF-a causes piloerection, diarrhea and 
withdrawal in mice, hypotension, tachypnea and respiratory arrest 
in rats, and fever in rabbits. Remick (47) studied the in vivo effects 
of human recombinant TNF-a in mice and induced hypovolemic shock, 
necrosis of the small bowel, fever, hypotension, malaise, and 
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respiratory failure. Kinkhabwala (49) has shown that normal 
activated T cells express TNF-a on their cell surface. He postulated 
that cell bound TNF, which is an important mediator of the 
inflammatory response and is implicated in host defense, is 
advantageous while the secreted TNF mediates the explosive clinical 
syndrome. Likewise, interferon-y (IFN-y), produced by T cells, seems 
to work in synergism with TNF for cell cytotoxicity. 
OKT3 and Lvmphokine Production 
Because OKT3's first dose reaction was similar to lymphokine 
induced clinical symptoms, investigators attempted to measure if 
lymphokine levels were increased after OKT3 administration. 
Suthanthiran (5) demonstrated that OKT3 added to peripheral blood 
lymphocyte culture promoted an increase in the level of IL-2 and 
IFN-y. 
Abramowicz (8) studied renal transplant recipients who 
received OKT3 for nonrejection prophylaxis. Lymphokine release 
was measured after exposure to OKT3 (with 1 mg/kg of methyl 
prednisolone) or to cyclosporine at 6 mg/kg. In the cyclosporine 
patients, TNF did not increase, and IL-2 and IFN levels were 
undetectable. In contrast, OKT3 induced a marked rise in IL-2 (peak 
2 hr), IFN (peak 2 hr) and TNF (peak 1 hr). Lasting only 24 hours, 
these rises were transient. Furthermore, in 78% of the OKT3 treated 
patients, subsequent doses of OKT3 did not induce a significant 
release of these lymphokines. 
Meanwhile, Chatenaud (7), using 17 patients, showed that the 
first, and only the first, dose of OKT3 caused a sharp increase of 
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IFN-y and TNF-a. In 3 patients who had received a haploidentical 
graft from a family member and had not received steroids, IL-2 was 
also increased. The peaks of lymphokine levels were similar to the 
previous study except that IFN and IL-2 both peaked at 4 hours. The 
rise in lymphokine levels resolved in 15-20 hours and did not recur 
with the second dose. No changes in IL-113 and IFN-a were detected 
at any time point. In an extension of the study to 35 patients, 
similar results were obtained (6). This increase in lymphokines 
paralleled temporally the reversible clinical syndrome. The 
difference in the two studies (6 and 8) which may explain the 
different IL-2 levels is that Abramowicz used much lower doses of 
steroids than Chatenoud (1 mg/kg vs 1g). 
Bloemena (50) has recently implicated IL-6, an inducer of 
acute phase hepatic proteins, as another mediator. He suggested 
that even though IL-6 levels are raised during rejection, they are 
increased significantly more after OKT3. Because the peak of IL-6 
was 48 hours, he suggested that IL-6 could mediate some of the late 
side effects associated with OKT3. 
Multiple studies (50-54) have shown that all lymphokines are 
elevated during rejection. However, the level of circulating 
lymphokines increases even more after OKT3 administration. 
OKT3-Tcell activation-Lvmphokines 
Thus far, the ideas that OKT3 causes a first dose reaction, that 
this reaction mimics the clinical picture of lymphokine release, and 
that OKT3 causes an increase in lymphokine release (in vitro and in 
vivo) have been discussed. Other studies have indicated that T cells 
■ 
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are responsible for lymphokine production after activation by other 
mitogens (55-58). How does one resolve the conflicting evidence 
that OKT3 is a powerful immuno-suppressant and that OKT3 induces 
a release of lymphokines, products of T cell activation? Prior to 
examining blood levels of lymphokines, most investigators 
(10,20,21,59,60,61,62) explained the adverse drug reaction to OKT3 
as resulting from endogenous pyrogens which were released by 
opsonized cells, lysed in the reticulo-endothelial system. Some 
problems with this theory include that other anti-T cell antibodies 
which induce opsonization do not cause a similar syndrome and that 
very small amounts of active lymphokines are stored within 
lymphocytes. 
Therefore, another mechanism was needed to explain how OKT3 
induced a lymphokine increase - OKT3 is not only a powerful 
immunosuppressant but also a T cell mitogen, capable of inducing 
activation and proliferation. In 1980, van Wauwe (63) showed that 
OKT3 was a potent mitogen of peripheral lymphocytes in vitro. 
Measuring 3H thymidine incorporation as an indication of T cell 
activation, he showed that OKT3 had definite mitogenic activity, 
even greater than phytohemagglutinin (PHA) and concanavalin A (CON 
A). Furthermore, OKT3 displayed no inhibition of response at high 
concentrations. 
Von Wussow (64) demonstrated that T lymphocytes which 
expressed CD3 antigen produced IFN after OKT3 was added to the 
medium. The timing of maximum activity of IFN (3-6 hours) 
correlated with in vivo studies (4 hours). Chang demonstrated that a 
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certain subset of T cells, CD4+ cells, secreted IFN (peak 3 hours) and 
that macrophages played an accessory role. Another study (65) 
implied that OKT3 induced IL-2 and IL-2R production, while others 
(66) showed that OKT3 induced production of TNF mRNA. 
Furthermore, Suthanthiran (5,13), performing in vitro studies, 
demonstrated that OKT3 caused T cells to become activated, induced 
both secondary cytolytic activity and natural killer activity, and 
increased the levels of IL-2 and IFN. 
Because most circulating blood cells are CD3- after OKT3 use, 
Ellenhorn (67) examined lymph node cells and offered the first in 
vivo support for T cell activation by OKT3. OKT3 coated lymph node 
T cells showed increased proliferation in vitro in presence of IL-2 
and increased expression of IL-2R. Several studies (4,68,69,70) 
have demonstrated a requirement of macrophages for OKT3 induced 
activation to occur. Ceuppens (70) discussed a family which failed 
to respond mitogenically to OKT3 but did respond to other mitogens; 
this lack of response was restored with the addition of 
macrophages. In contrast, others have demonstrated mitogenesis in 
macrophage free media (5,63,64,66). 
The clinical setting of OKT3 administration may play an 
important role in the amount of lymphokines released and the 
severity of the subsequent first dose reaction. When used in the 
acute post-operative period, OKT3 may have different side effects 
than when used for treatment of rejection - although some 
investigators found no difference(37). Postulating that T cells had 
not been activated by rejection, some researchers(34,39,71) implied 
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that OKT3 used as prophylactic agent had fewer side effects. Also, 
the drug was often-times giving peri-operatively, and the patient, 
under anesthesia, would have been unable to report some of the side 
effects. Others (25) believed that prophylactic use of OKT3 carried 
increased risk for adverse drug reactions because there was no prior 
exposure to immunosuppressants. 
Concomitant immunosuppression plays an important role in 
cytokine release from T cells and in OKT3 related symptoms. 
Cyclosporine may act in vitro to inhibit mitogen directed 
activation(72), permit suppressor T cell proliferation(73), and 
inhibit production of both IL-2 (74) and IFN (75). Also, 
corticosteroids(51,75) inhibit IL-1 dependent release of IL-2, 
inhibit IFN release and have general lymphopenic effects (56,76,77) 
- which would decrease the number of T cells exposed to OKT3. 
Several investigators have examined if concomitant 
immunosuppressives affect lymphokine levels post OKT3 
administration. Suthanthiran (5) has shown that cyclosporine and 
methyl prednisolone caused a marked inhibition of memory T cell 
proliferation and of cytotoxic lymphocyte activity. IL-2 production 
was markedly decreased by cyclosporine and mildly by methyl 
prednisolone; both equally inhibited release of TNF. Another 
investigator (6) determined that methyl prednisolone exerted its 
greatest effects in decreasing OKT3 related side effects if it was 
given in high doses (500mg) 15-60 minutes prior to OKT3. 
Gaston published a report (78) indicating the importance of 
TNF as the cause of OKT3 related side effects. Fie used a graded 
■ 
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scale (0-3) for four symptoms (fever, headache, dyspnea, rigors). 
Patients were separated into two groups, based on the number of 
side effects reported. The total number of CD3+ cells and of CD4+ 
cells prior to OKT3 administration were higher in the group with the 
more severe reaction. As with other studies, the peak of TNF at 2 
hours correlated well with the severity of the reaction. He showed 
no rise in IFN or IL-2. All patients were premedicated with 250 mg 
of methyl prednisolone which could account for the lack of increase 
in IL-2. He postulated that T cell activation rather than lysis was 
the cause of the increased levels of TNF and the subsequent adverse 
reaction. 
Based on the above mentioned studies, it is now thought that 
OKT3 is a powerful immunosuppressant and it possesses immuno- 
activating abilities that are dose related. Because CD3+ cells are 
removed from circulation (by opsonization or modulation) and are 
unable to react, lymphocyte activation, and hence clinical reaction 
to OKT3, may not exist after the first or second dose of OKT3. 
Murine Model 
A murine model for OKT3 exists which further supports the 
role of OKT3 as a mitogen, capable of stimulating lymphokine 
release and producing a symptom complex. Immunizing Armenian 
hamsters with murine cytolytic T cell clone, Leo (79) has developed 
a monoclonal antibody (145-2c11) which is a murine analog to OKT3. 
This monoclonal antibody is directed at the CD3e component of the 
TCR/CD3 complex. It can act also as a T cell mitogen, inducing non¬ 
antigen specific lysis and T cell proliferation. Hirsch (80,81) 
' 
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classified further 145-2c11 actions, finding that it produced a rapid 
depletion of peripheral T cells and a delayed and incomplete 
depletion of T cells in lymphoid tissue. This antibody induced a 
modulation of TCR and a mitogenic response in T cells. 
Immunosuppressive abilities of 145-2c11 were demonstrated by 
increased graft survival time and decreased cytotoxic T lymphocytes 
activity. Because rapid and extensive lysis did not occur within the 
first 2 days of therapy, the adverse drug reaction secondary to the 
monoclonal antibody was probably not due to lysis. They postulated 
that this reaction may be secondary to the reactivation of latent 
viruses as the adverse drug reactions did not appear in hepatitis 
free mice. This monoclonal antibody also caused IL-2R expression, 
IL-2 secretion, and extra-medullary hematopoiesis in the spleen. 
Others (82-85) utilized this monoclonal antibody to address 
further the issue of OKT3 promoting lymphokine release, a proposed 
cause of the first dose reaction. In vivo injection of 145-2c11 in 
mice caused a transient increase in TNF, IFN, IL-2, IL-3, and IL-6 
that paralleled a symptom complex consisting of hypothermia, 
diarrhea, hypomotility, piloerection, and somnolence. 
Histopathology included cell necrosis and edema in lymphoid organs 
and edema/congestion of lung, liver and Gl tract. Serving as a 
control, anti-CD4 antibodies did not elicit a lymphokine release or 
the clinical picture. These studies helped link the clinical reaction 
to the release of lymphokines because the kinetics of increased 
lymphokines were superimposable with the clinical picture, the 
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kinetics were similar to OKT3, and the reaction was similar to that 
described after lymphokine administration. 
Prevention of First Dose Reaction 
In an attempt to prevent the first dose reaction to OKT3, 
various protocols have been implemented. Many protocols have 
included pretreatment 30 minutes prior to OKT3 with 
diphenhydramine, acetaminophen, and glucocorticoids. Some 
protocols also require glucocorticoids (100 mg hydrocortisone) 30 
minutes after OKT3 use. However, no study has analyzed the 
potential protective effects of the different protocols on the 
incidence or severity of OKT3 induced side effects. One would 
anticipate that drugs which inhibit lymphokine release after 
lymphocyte activation might be useful in blocking this reaction. 
Calcium Entry - A Step in T Cell Activation 
One might postulate that if more were known about the 
mechanism of OKT3 induced mitogenicity, one could develop a 
treatment to inhibit the side effects. Tsien (86) helped introduce 
the potential role of calcium as an important mediator of T cell 
activation. He developed a technique (Quin 2) to measure directly 
the intracellular calcium concentration in mitogen stimulated T 
cells, which showed a 2 fold increase in calcium. Calcium free 
medium and agents that increased cAMP, which were both known to 
inhibit mitogenesis, inhibited this calcium response. 
In a review of the role of calcium in lymphocyte proliferation 
(87), Lichtman discussed that calcium uptake by the cell occurred 
after mitogen stimulation, which lead to 3H thymidine uptake in the 
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DNA and subsequent mitosis. This activation effect was blocked by 
EGTA, a calcium chelator. Furthermore, the calcium ionophore 
A23187 induced both calcium and 3H thymidine uptake and served as 
a T lymphocyte mitogen. Mills (88,89), also using Quin 2, showed an 
association between phytohemagglutinin (PHA) induced calcium 
uptake by cell and 3H thymidine uptake by DNA; both were blocked by 
EGTA, as was PHA induced IL-2 production. He concluded that T cell 
mitogenesis did not occur without an initial calcium flux. 
Mitogens such as PHA and concanavalin A (con A) may require a 
calcium flux for T cell activation, but does OKT3? Researchers(2) 
have suggested that OKT3 promoted a significant increase in 
intracellular calcium. Using a CD3 negative (CD3-) culture, they 
also demonstrated that the calcium ionophore could obviate the need 
for the CD3 antigen in producing mitosis. Because normal mitogens 
(PHA) did not cause an increase in intracellular calcium in CD3- 
cells, the researchers linked mitogenesis to increased calcium and 
CD3 transduction of signal. Oettengen (4) speculated that one of the 
3 chains of the CD3 complex was the actual calcium channel and that 
the antigen-bound TCR served to activate this calcium channel. He 
also showed that OKT3 induced an intracellular increase in calcium 
which was dependent upon extracellular calcium, was sensitive to 
membrane polarization, and was blocked by lanthanum, a calcium 
channel blocker. 
Calcium Channel Blockers - Inhibition of T Cell Activation 
Several studies have examined whether calcium channel 
blockers are effective in inhibiting T cell activation. Gearing (90), 
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using 3H thymidine uptake as measure of proliferation in rat blast 
cells and in a murine T cell clone, demonstrated that both verapamil 
and nifedipine at doses of 10 ug/ml inhibited IL-2 induced 
proliferation. G rie r(91), using con A to stimulate bovine 
retropharyngeal lymphocytes, showed that verapamil inhibited 3H 
thymidine incorporation in a dose dependent manner (20% at 2 uM, 
40% at 10 uM, and 60% at 20 uM). Another study, by McMillan(92), 
showed, that at doses more than 10 uM, verapamil inhibited murine T 
cell proliferation to alloantigen and con A. 
Other studies, using peripheral blood mononuclear cells from 
healthy volunteers, have analyzed the effects of calcium channel 
blockers on human T cell activation. Larson (93) showed that 
verapamil at 10 ug/ml inhibited IL-2 induced 3H thymidine uptake by 
20%, whereas the maximal inhibition was seen at 60 ug/ml. Walz 
(94), using phytohemagglutinin and phorbol myristate acetate as 
mitogens, demonstrated that verapamil required levels of at least 
30 uM to have inhibiting effects on 3H thymidine uptake, calcium 
influx, and levels of IL-2 mRNA. Birx(95) determined the dose of 
three calcium channel blockers required to produce a 50% inhibition 
to con A (verapamil at 15 uM, nifedipine at 24uM, and diltiazem at 
80 uM). Furthermore, Weir (96), varying doses of verapamil at 0.5 
uM, 5 uM and 50 uM, demonstrated an inhibition of mRNA production 
at 3%, 24% and 84%, respectively, and an inhibition of new protein 
synthesis at 0%, 14% and 61%, respectively. 
Therefore, it appears that calcium channel blockers inhibit T 
cell mitogenesis in vitro in a dose dependent manner. The 
. 
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therapeutic plasma concentration for each of the three calcium 
channel blockers (verapamil, nifedipine, and diltiazem) is less than 
200 ng/ml, or less than 0.5 uM (94,97,99-103). This level is less 
than the in vitro level shown in the previous studies to inhibit T cell 
mitogenesis. Weir (97) addressed the question of whether OKT3 
stimulation of T cells was similarly affected. He incubated a 
culture of peripheral blood mononuclear cells from healthy adult 
donors with 3 ug/ml of OKT3 for 3 days. In a dose dependent 
fashion, verapamil inhibited OKT3 induced T cell proliferation by 
22% at 0.5 uM, 30% at 5 uM, and 76% at 50 uM. 
Madreoli (98) studied the immunological status of renal graft 
recipients who received calcium channel blockers for one month. 
The patients chosen for the study had shown no signs of rejection, 
nephrotoxicity nor viral infection and had been on an 
immunosuppressive therapy consisting of cyclosporine. He suggested 
that calcium channel blockers inhibited the mitogenic response to 
PHA and promoted an increase in CD8+ cells. More importantly, he 
used therapeutic doses of Nicardipine (60mg/day) and Diltiazem 
(90mg/day). Because the calcium channel blockers caused no change 
in the non calcium dependent poke weed mitogen, he concluded that 
calcium channel blockers work by blocking a calcium channel 
necessary for T cell activation. Madreoli implied that calcium 
channel blockers may inhibit T cell activation at normal therapeutic 
doses. 

20 
Purpose 
To determine whether clinically used doses of calcium channel 
blockers are effective in ameliorating first dose reactions to OKT3. 
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Methods 
A retrospective study was performed on all renal transplant 
patients who had received OKT3 between December 1983 (when OKT3 
became available) and July 1990 (when this analysis began). 
Transplantation flow sheets (a daily record of a patient's hospital 
course) and discharge summaries were used to determine which 
patients had received OKT3 and the reason for its use. The patient 
population is described in Table 1. Pediatric cases were excluded 
from the study because this patient group may not reliably report 
symptoms. 
The patients received OKT3 either to treat resistant rejection 
(19 in calcium channel blocker group vs 42 in control) or to avoid 
cyclosporine toxicity in the setting of delayed graft functioning (1 
in calcium channel blocker group versus 7 in control). 
Administration of OKT3 (5mg/day intravenously) was preceded 30 
minutes by acetaminophen (650 mg), diphenhydramine (25-50 mg), 
and corticosteroids. Some patients (N=31) received hydrocortisone 
100 mg 30 minutes after OKT3. Because of the incidence and 
severity of first dose reactions, a physician administered the OKT3 
while a nurse monitored for a reaction. 
The hospital records were studied for demographic 
information, including age, sex, race, days of OKT3 therapy, and days 
post-op from transplant until OKT3 was given. Dialysis was defined 
by the patient undergoing dialysis (hemo or peritoneal) 1 day prior to 
OKT3 or up to 2 days after OKT3 was begun. Concomitant 
immunosuppressives, including azathioprine, cyclosporine, and 
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glucocorticoids, were recorded. Glucocorticoid doses were 
converted to methyl prednisolone equivalents using the following 
formula (4mg methyl prednisolone = 5 mg prednisone = 20 mg 
hydrocortisone). 
The signs and symptoms of first dose reactions following the 
first 48 hours of OKT3 were recorded for each patient, and the 
definitions used are included in Table 2. The signs and symptoms 
analyzed in this study were chosen for their generally accepted 
occurrence after the first dose of OKT3 in studies that included 
more than 30 patient episodes (20,22,25,27,34,38,43,44). 
Most of the information was obtained from the progress notes 
of the attending surgeons, the residents, and the nurses. Presence of 
fever, changes in blood pressure, tachycardia, emesis, and diarrhea 
were also checked on the nurses flow sheets. Trough blood levels of 
cyclosporine were obtained from a Chemistry Lab Data Sheet. The 
actual dosage and timing of all the medications were determined 
from the nursing record of drug administration. 
The data were then analyzed to determine whether first dose 
reactions were less severe in those on calcium channel blockers 
(N=20) versus those off (N=49). To be included in the calcium 
channel blocker group, a patient had to be on calcium channel 
blockers for at least 3 days prior to the initiation of OKT3. Patients 
were receiving calcium channel blockers for the treatment of 
hypertension and angina. These patients did not receive calcium 
channel blockers for the treatment of rejection or for the prevention 
of reaction to OKT3. The number who received each type of calcium 
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channel blocker, the mean dose, and the range of doses are as 
follows : (Nifedipine : N=13, mean dose 66.2mg, range 30-120mg; 
Verapamil : N=5, mean 248mg, range 120-480mg; Diltiazem : N=2, 
mean 135mg, range 90-180mg). Patients receiving PRN nifedipine 
for hypertension (N=4) were not included in the calcium channel 
blocker group unless the total dose was greater than 30mg per day. 
Statistics 
All data were analyzed using chi-square analysis and Student 
T-tests with a SAS statistical program. The cyclosporine doses 
were compared also with Wilcoxon Rank-Sum test. These statistical 
tools were employed after consultation with bio-statisticians from 
Yale University School of Epidemiology and Public Health. 
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Results 
At the time of OKT3 administration, 20 patients were on 
calcium channel blockers and 49 were not (Table 3). There were no 
significant differences between the two groups in age, sex, race, 
percent cadaveric transplants, and percent on dialysis. At the time 
of OKT3 administration, the dose and level of cyclosporine, the dose 
of azathioprine, and the dose of glucocorticoid were not different in 
the two groups. 
Table 4 shows the percentages of the symptoms present in the 
two groups. Nearly 90% of each group developed fever. The peak 
temperature in the patients on calcium channel blockers was 102 ±. 
0.3°F (range 99.3-104.4) which was identical to the peak in those 
not on calcium channel blockers, 102 ±. 0.2°F (range 98.8-105.0). 
Chills, gastrointestinal symptoms, respiratory complaints, and 
hemodynamic change were similar in both groups. Symptoms 
relating to lethargy and fatigue were the only ones that did differ 
between the two groups, occurring twice as frequently in the 
calcium channel blocker group. 
Five patients received OKT3 on two different occasions, once 
on calcium channel blockers at the time OKT3 administration and 
once off. In general, each patient had similar reactions to the OKT3, 
regardless of presence of calcium channel blockers. 
. 
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Discussion 
A powerful immunosuppressant, OKT3 monoclonal antibody is 
used primarily to treat steroid resistant rejection or to protect the 
kidney from cyclosporine toxicity in the setting of post-transplant 
delayed graft functioning. The first and second doses of OKT3 are 
often accompanied by adverse reactions, ranging from a mild 
nuisance to life threatening sequelae. Various cytokines, namely 
TNF, IL-2, IFN, rise after OKT3 administration, in parallel with the 
appearance of the clinical syndrome. Because OKT3 has been shown 
to be a T cell mitogen, these cytokines are believed to be the product 
of T cell activation/proliferation, rather than T cell lysis. Calcium 
has been shown to be an important mediator of T cell activation 
after OKT3, and calcium channel blockers decrease T cell activation 
in vitro after stimulation with mitogens, including OKT3. This study 
attempted to determine whether clinically used doses of calcium 
channel blockers could effectively decrease the symptoms 
associated with the use of OKT3. 
The frequencies of signs and symptoms of first dose reaction 
to OKT3 observed in this study are similar to the frequencies found 
by other investigators (20,22,25,27,34,38,43,44). Even though 
patients were not previously randomized, patient demographics, 
including immunosuppressive regimens at the time of OKT3 
administration, were similar in the two groups. This study 
demonstrated that calcium channel blockers apparently offer no 
protection against the first dose reaction of OKT3. Analysis of peak 
temperature showed no difference between the two groups. 
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The reason why calcium channel blockers caused more fatigue 
is not clear. All calcium channel blockers can cause fatigue, which 
is usually tolerated with subsequent doses. There was no reason to 
suspect an inherent difference in the two groups regarding 
perception of or reporting of fatigue. Furthermore, because 16 
different symptoms/signs were analyzed with significance looked 
for at P=0.05 level, there is a high likelihood that one of the factors 
would be significant purely based on chance. 
What are the possible explanations for the lack of a protective 
effect of calcium channel blockers against first dose OKT3 
reactions? Firstly, clinically used doses of calcium channel 
blockers may not achieve high enough blood levels to inhibit OKT3 
induced T cell activation. The therapeutic plasma concentration for 
each of the three calcium channel blockers (verapamil, nifedipine, 
and diltiazem) is less than 200 ng/ml, or less than 0.5 uM 
(94,97,99-103). In all the in vitro studies (90-95) which used 
mitogens other than OKT3, the levels of calcium channel blockers 
required to inhibit T cell proliferation were substantially higher 
than the normal therapeutic level of 0.5uM by 1 to 2 orders of 
magnitude (5uM to 50uM). Several studies (94,95) demonstrated no 
inhibition at 0.5 uM while the others did not test at concentrations 
this low. The only in vitro study using OKT3 as the T cell mitogen 
(96) did show a 22% inhibition of T cell activation at 0.5 uM of 
verapamil. However, it is possible that such a small degree of 
inhibition, if it also occurs in vivo, is not sufficient to decrease the 
signs and symptoms related to lymphokine release. Because our 
• • 
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patients had received typical doses of calcium channel blockers for 
at least three days prior to receiving OKT3, blood levels, although 
not directly measured, were assumed to be in the therapeutic range. 
In vitro studies using OKT3 as the T cell mitogen should be repeated 
to determine if levels of calcium channel blockers achieved 
therapeutically (ie. less than 200 ng/ml) inhibit T cell proliferation. 
As always, however, the in vitro work may not be directly applicable 
to clinical settings. 
Not all calcium channels blockers possess the same qualities. 
Carteza (104) studied the effects of calcium channel blocker on in 
vivo delayed type hypersensitivity in mice. Sensitizing mice with 
the antigen oxazolone, he found that nifedipine had significant 
suppressing effects, verapamil had significant enhancing effects, 
and diltiazem had no effect. Because the total number of patients on 
calcium channel blockers in this present study was small, the effect 
of the three individual calcium channel blockers could not be 
analyzed separately. 
As the study was retrospective, the patients were not 
randomized prospectively to calcium channel blockers. The patients 
received calcium channel blockers for the treatment of hypertension 
and angina. The patients did not receive the blockers for the 
treatment of rejection or for the protection against the first dose 
reaction to OKT3. Some patients in the control group who had angina 
or hypertension were treated with different agents. The data were 
not examined to determine if the underlying indication for calcium 
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channel blockers could be responsible for the lack of any observable 
differences. 
In this study, five patients received OKT3 twice, once on 
calcium channel blockers and once off them. Albeit a small number 
to analyze, there was no discernable difference in the side effects 
for each individual patient for the two different episodes. For each 
patient, the second episode of OKT3 caused a reaction that was 
similar to the first episode. The individual results in these five 
patients, with each one serving as his/her own control, strongly 
support our final conclusion about the absence of protection with 
calcium channel blockers. 
The number of patients in this study was relatively small. 
Only 69 patient episodes of OKT3 could be found over a 6.5 year span, 
with an uneven distribution (20 on calcium channel blockers vs 49 
controls) between the two groups. Perhaps with a larger, more 
evenly distributed sample, a different result would bear out. 
However, the data does not suggest that there was even a tendency 
toward a less severe reaction in our patients on calcium channel 
blockers. 
Our study was a retrospective one. Because of the small 
number of patients receiving calcium channel blockers over the 
relatively long time frame, we had to chose this method. However, 
because the nurses and/or the intern closely monitors the 
hemodynamics and the temperature during the first few hours and 
because more objective symptoms such as vomiting/diarrhea are 
generally recorded by nurses on a daily flow sheet, these symptoms 
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were likely to be adequately recorded. In addition, there was no 
reason to suspect observer or recorder bias in either group. 
Although a prospective study would have allowed more detailed 
analysis of each sign and symptom, it is likely that the final result 
would be the same. 
Koch-Weser (105) has pointed out that adverse drug reactions 
can be very ambiguous events, promoting widely divergent responses 
from clinical pharmacologists. One must first determine if an 
actual drug reaction is the proper etiology of the symptoms (as 
opposed to an illness) and then determine which drug caused it. In 
our patient population, not only are multiple disease states present 
(transplant, post-op, hypertension, rejection, etc) but so are 
multiple drug regimens. However, because reaction to OKT3 occurs 
so frequently and with a recognizable clinical syndrome, OKT3 is 
probably responsible for the clinical syndrome experienced by our 
patients. Because OKT3 induced side effects occur only with the 
first doses, reproduction of the syndrome with OKT3 rechallenge is 
difficult. However, as mentioned previously, the 5 patients who had 
received OKT3 (while on calcium channel blockers and while off 
them) had similar reactions both times. 
In order to improve upon both reproducibility and validity, it is 
important to use explicit criteria for inclusion of a sign or 
symptom(106-108). As noted in the methods, this study did use 
explicit criteria. However, the adverse drug reactions were 
determined by one person (should be multiple) and at one time (if 
same person, should be repeated at later date). Because the 
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incidence of side effects in this study is similar to that reported in 
other studies, it is likely that retrospective studies are a valid 
means of testing for OKT3 associated side effects if explicit 
criteria are used (105-108). 
In summary, in our study, calcium blockers did not protect 
against first dose reactions to OKT3. The best explanation to 
account for this result is that clinically used calcium channel 
blockers do not attain a high enough serum level to inhibit OKT3 
induced T cell activation. 
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Table 1 Patient .Population 
Category Number of Ppis,Q.cle.s 
Transplant recipients (1983-1990) 224 
OKT3 episodes(a) 8 0 
Files not used(b) -11 
OKT3 episodes in study 6 9 
Episodes on calcium channel blockers 2 0 
Episodes not on calcium channel blockers 49 
(a) An episode of OKT3 use (to treat rejection or used 
prophylactically to prevent cyclosporine toxicity in the early 
post transplant period) 
(b) 2 files not found, 1 confidential file, 5 pediatric cases, 
3 pancreas/kidney recipients 

Table 2 Definitions of Signs and Symptoms 
Fever - Temperature > 100 F in first 48 hours with negative cultures 
Chills - Complaint of chills, rigors 
Dyspnea - Complaint of shortness of breath, trouble breathing 
Wheeze - Complaint of wheeze, or noticed on physical exam 
Chest pain - Complaint of chest pain or chest tightness 
Emesis - Presence of vomiting 
Diarrhea - Presence of diarrhea 
Headache - Presence of headache 
Seizure - New onset of seizure and witnessed by med staff 
Malaise - Complaint of lethargy, extreme fatigue 
Aseptic meningitis - Lumbar puncture showing white blood cells in 
cerebral spinal fluid with negative cultures 
Tachycardia - Heart rate > 100 
Hypotension - Systolic < 90 or decrease in systolic > 20 mm Hg 
Hypertension - Systolic > 160 or increase in systolic > 20 mm Hg 
Arthralgia - Complaint of joint aches/pains 
Myalgia - Complaint of muscle aches/pains 

Table 3 Comparison of Demographic Data 
Calcium, Channel Blocker 
(N=20) 
Control 
(N=49) 
Variable 
Sex (% Male) 51 70 
Age (years) (a) 37.3 ± 2.9 36.8 ± 1.8 
Race (% Black) 1 5 1 8 
Transplant Type 90 78 
(% cadaver) 
Dialysis (b) 45 49 
Days post transplant (c,d) 27 (0-1874) 21 (0-995) 
CSA Dose (mg/day)- 485.5 ± 87 342.2 ± 61 
Day Before (a) 
CSA Level (ng/ml)- 118.3 ± 33 81.8 ± 15 
Day Before (a) 
CSA Dose (mg/day)- 390.0 ± 81 239.0 ± 49 
Day of OKT3 (a) 
CSA Level (ng/ml)- 124.7 ± 31 114.8 ± 21 
Day of OKT3 (a) 
Imuran dose (mg) (a) 11.8 ± 6.8 17.3 ± 6.0 
Solumedrol dose (mg) 301.9 ± 90 271.1 ± 34 
(24 hour before OKT3) (a) 
Solumedrol dose (mg) 104.4 ± 31 134.3 ± 25 
(1 hour before OKT3) (a) 
a Mean ± standard error of mean 
b Percent of patients on dialysis 
c Days after transplant when OKT3 was started 
d Median (Range) 

Table 4 Signs and Symptoms of First Dose Reaction to OKT3(a) 
Calcium Channel Blocker Control 
(N=20) (N=49) 
Siqn/Svmptom(b) Percent(c) Percent(c) 
Fever 90 88 
Malaise 70 * 33 
Chills 60 41 
Tachycardia 50 51 
Emesis 50 35 
Hypertension 45 45 
Diarrhea 40 45 
Myalgia 35 1 6 
Hypotension 30 23 
Arthralgia 30 1 6 
Headache 25 43 
Dyspnea 25 23 
Wheeze 20 8 
Chest Pain/Tightness 15 1 4 
Aseptic Meningitis 10 4 
Seizure 0 0 
* P < 0.005 by chi-square analysis 
a Within first 48 hours 
b Criteria for each sign/symptom is listed in Table 2 
c Percent in each group with a given sign or symptom 
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